205 related articles for article (PubMed ID: 27095671)
1. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Sinha BK; Kumar A; Mason RP
Biochem Biophys Rep; 2017 Jul; 10():252-259. PubMed ID: 28955753
[TBL] [Abstract][Full Text] [Related]
3. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
[TBL] [Abstract][Full Text] [Related]
4. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
6. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
7. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
8. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
12. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
14. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
15. UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.
Mann MJ; Pereira ER; Liao N; Hendershot LM
PLoS One; 2012; 7(10):e47931. PubMed ID: 23144714
[TBL] [Abstract][Full Text] [Related]
16. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
17. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
18. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
19. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
20. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
